Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0260113
Abstract: In the backdrop of rapidly changing relapsed/refractory (RR) multiple myeloma (MM) treatment schema that mainly evolves around immunotherapies, it is easy to disregard more traditional drugs. Finding the best partner for pomalidomide, a potent third-generation… read more here.
Keywords: addition; cyclophosphamide addition; pomalidomide dexamethasone; treatment ... See more keywords